New Data Bolster Tecentriq Bid To Be First Adjuvant Immunotherapy In NSCLC
US FDA Decision Expected 1 December
Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.
You may also be interested in...
Opdivo gets approved by the US FDA for neoadjuvant non-small cell lung cancer, an important new early-stage indication for the anti-PD-1 agent that cleared the agency in roughly two months.
Roche has not disclosed the full data yet, but is confident that Polivy can surpass CAR-Ts and other competitors to be the new standard of care.
An executive told Scrip the company hopes to target all-comers as well as PD-L1-positive patients.